• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.

作者信息

Schreiber Karen, Sciascia Savino, Bruce Ian N, Giles Ian, Cuadrado Maria J, Cohen Hannah, Gordon Caroline, Isenberg David, Jacobsen Søren, Middeldorp Saskia, Mosca Marta, Pavord Sue, Radin Massimo, Roccatello Dario, Salmon Jane, Vinet Evélyne, Voss Anne, Watkins Linda, Hunt Beverley J

机构信息

Danish Hospital for Rheumatic Diseases, 6200 Sonderborg, Denmark.

Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust, London, UK.

出版信息

Lancet Rheumatol. 2020 Dec;2(12):e735-e736. doi: 10.1016/S2665-9913(20)30382-9. Epub 2020 Oct 29.

DOI:10.1016/S2665-9913(20)30382-9
PMID:33163976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7598898/
Abstract
摘要

相似文献

1
Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.新型冠状病毒肺炎大流行期间风湿性疾病患者使用羟氯喹：致临床医生的一封信
Lancet Rheumatol. 2020 Dec;2(12):e735-e736. doi: 10.1016/S2665-9913(20)30382-9. Epub 2020 Oct 29.
2
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.COVID-19、羟氯喹和心脏性猝死：对风湿性疾病患者临床实践的影响。
Rheumatol Int. 2021 Feb;41(2):257-273. doi: 10.1007/s00296-020-04759-2. Epub 2021 Jan 1.
3
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.新冠疫情时代民众对抗风湿药物的关注度：来自谷歌趋势的见解
Clin Rheumatol. 2021 May;40(5):2047-2055. doi: 10.1007/s10067-020-05490-w. Epub 2020 Oct 31.
4
Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.慢性使用羟氯喹并未在巴西的一大群风湿疾病患者中预防 COVID-19。
Adv Rheumatol. 2021 Oct 7;61(1):60. doi: 10.1186/s42358-021-00217-0.
5
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.意大利风湿患者使用羟氯喹或其他传统疾病修正抗风湿药物治疗的 2019 年冠状病毒病住院和死亡风险。
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI25-SI36. doi: 10.1093/rheumatology/keab348.
6
Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study.炎症性风湿性疾病患者中羟氯喹与心电图及超声心动图异常之间的可能关系——一项单中心研究
Lupus. 2023 Mar;32(3):388-393. doi: 10.1177/09612033221149875. Epub 2023 Jan 4.
7
Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran.在伊朗大流行的第一波和第二波期间，生物制剂和传统改善病情抗风湿药物对风湿病患者中新冠病毒感染发病率的影响。
Reumatologia. 2022;60(4):231-241. doi: 10.5114/reum.2022.119039. Epub 2022 Sep 7.
8
Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy.风湿性疾病患者使用和不使用羟氯喹治疗的 2019 冠状病毒病（COVID-19）发病率相似。
PLoS One. 2021 Apr 8;16(4):e0249036. doi: 10.1371/journal.pone.0249036. eCollection 2021.
9
Influence of the COVID-19 Pandemic on Medical Management and on Healthcare Delivery of Immune-Mediated Rheumatic and Musculoskeletal Diseases during the First Pandemic Period February to July 2020: A Systematic Review.2020年2月至7月第一波疫情期间新冠疫情对免疫介导的风湿性和肌肉骨骼疾病的医疗管理及医疗服务的影响：一项系统综述
Medicina (Kaunas). 2024 Apr 4;60(4):596. doi: 10.3390/medicina60040596.
10
Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.氯喹和羟氯喹——从风湿病学家的角度看潜在 COVID-19 药物的安全性概况。
Ann Agric Environ Med. 2021 Mar 18;28(1):122-126. doi: 10.26444/aaem/127766. Epub 2020 Oct 8.

引用本文的文献

1
Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?皮肤科药物治疗 2019 年冠状病毒病的再利用：科学还是虚构？
Clin Dermatol. 2021 May-Jun;39(3):430-445. doi: 10.1016/j.clindermatol.2021.01.020. Epub 2021 Feb 2.
2
Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence.狼疮之外的炎性和自身免疫性风湿及肌肉骨骼疾病中的抗磷脂抗体：现有证据的系统评价
Rheumatol Ther. 2021 Mar;8(1):81-94. doi: 10.1007/s40744-020-00273-w. Epub 2021 Jan 9.

本文引用的文献

1
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
2
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.长期使用羟氯喹治疗风湿性疾病患者与感染严重急性呼吸综合征冠状病毒2的相关性：一项回顾性队列研究
Lancet Rheumatol. 2020 Nov;2(11):e689-e697. doi: 10.1016/S2665-9913(20)30305-2. Epub 2020 Sep 21.
3
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.最新警报：羟氯喹啉或氯喹啉用于治疗或预防2019冠状病毒病
Ann Intern Med. 2020 Aug 18;173(4):W78-W79. doi: 10.7326/L20-0945. Epub 2020 Jul 15.